Maude Bouscambert-Duchamp
Overview
Explore the profile of Maude Bouscambert-Duchamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Viermyr H, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas J, et al.
EBioMedicine
. 2024 Dec;
111():105511.
PMID: 39731852
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated...
2.
Beaulieu M, Gaymard A, Massonnaud C, Peiffer-Smadja N, Bouscambert-Duchamp M, Carcelain G, et al.
J Antimicrob Chemother
. 2024 Sep;
79(11):2887-2895.
PMID: 39236218
Background: The antiviral efficacy of Evusheld (AZD7442) in patients hospitalized for SARS-CoV-2 is unknown. Methods: We analysed the evolution of both the nasopharyngeal viral load and the serum neutralization activity...
3.
Hites M, Massonnaud C, Larranaga Lapique E, Belhadi D, Jamard S, Goehringer F, et al.
J Infect
. 2024 Feb;
88(3):106120.
PMID: 38367705
No abstract available.
4.
Neant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(12):2027-2037.
PMID: 37728045
The role of antiviral treatment in coronavirus disease 2019 hospitalized patients is controversial. To address this question, we analyzed simultaneously nasopharyngeal viral load and the National Early Warning Score 2...
5.
Galzin E, Roche L, Vlachomitrou A, Nempont O, Carolus H, Schmidt-Richberg A, et al.
Res Diagn Interv Imaging
. 2023 Jun;
4:100018.
PMID: 37284031
Objectives: We evaluated the contribution of lung lesion quantification on chest CT using a clinical Artificial Intelligence (AI) software in predicting death and intensive care units (ICU) admission for COVID-19...
6.
Queromes G, Frobert E, Bouscambert-Duchamp M, Oblette A, Valette M, Billaud G, et al.
J Med Virol
. 2022 Sep;
95(1):e28126.
PMID: 36089749
The emergence and sustained transmission of novel pathogens are exerting an increasing demand on the diagnostics sector worldwide, as seen with the ongoing severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic...
7.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentre F, Burdet C
Lancet Infect Dis
. 2022 Jun;
22(6):764-765.
PMID: 35643099
No abstract available.
8.
Venet F, Gossez M, Bidar F, Bodinier M, Coudereau R, Lukaszewicz A, et al.
EBioMedicine
. 2022 Mar;
78:103967.
PMID: 35349827
Background: In critically ill COVID-19 patients, the initial response to SARS-CoV-2 infection is characterized by major immune dysfunctions. The capacity of these severe patients to mount a robust and persistent...
9.
Lingas G, Neant N, Gaymard A, Belhadi D, Peytavin G, Hites M, et al.
J Antimicrob Chemother
. 2022 Mar;
77(5):1404-1412.
PMID: 35233617
Background: The antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. Objectives: To estimate the effect of remdesivir in blocking viral replication. Methods: We analysed nasopharyngeal normalized viral loads...
10.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al.
Lancet Infect Dis
. 2021 Sep;
22(2):209-221.
PMID: 34534511
Background: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone...